HUB Investment Partners LLC Sells 5,238 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

HUB Investment Partners LLC cut its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 34.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,112 shares of the biotechnology company’s stock after selling 5,238 shares during the period. HUB Investment Partners LLC’s holdings in ADMA Biologics were worth $173,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in shares of ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock worth $865,000 after buying an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in shares of ADMA Biologics by 1.3% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock worth $954,000 after buying an additional 700 shares during the last quarter. Mutual of America Capital Management LLC increased its holdings in shares of ADMA Biologics by 2.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock worth $614,000 after buying an additional 751 shares during the last quarter. Maryland State Retirement & Pension System increased its holdings in shares of ADMA Biologics by 1.1% in the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock worth $1,365,000 after buying an additional 897 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Price Performance

ADMA stock opened at $19.80 on Friday. ADMA Biologics, Inc. has a 12 month low of $5.90 and a 12 month high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a 50-day moving average price of $16.76 and a 200 day moving average price of $18.04. The stock has a market cap of $4.68 billion, a PE ratio of 70.71 and a beta of 0.60.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a research note on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.